As of 2026-06-16, the Intrinsic Value of GT Biopharma Inc (GTBP) is -6.62 USD. This GTBP valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.47 USD, the upside of GT Biopharma Inc is -1,512.14%.
Based on its market price of 0.47 USD and our intrinsic valuation, GT Biopharma Inc (GTBP) is overvalued by 1,512.14%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -6.62 - -6.62 | -6.62 | -1,512.14% |
| P/E | (26.47) - (33.31) | (30.71) | -6652.3% |
| DDM - Stable | (8.10) - (26.64) | (17.37) | -3805.6% |
| DDM - Multi | (1.87) - (5.06) | (2.76) | -688.9% |
| Market Cap (mil) | 16.90 |
| Beta | 1.01 |
| Outstanding shares (mil) | 36.06 |
| Enterprise Value (mil) | 7.98 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.96% |
| Cost of Debt | 5.00% |
| WACC | 7.81% |